Video
Karla Palmer, director at Hyman, Phelps, & McNamara, discusses how the Hemp Farming Act of 2018 affected hemp and CBD products.
Karla Palmer, director at Hyman, Phelps, & McNamara, discusses how the Hemp Farming Act of 2018 affected hemp and CBD products. This video was filmed at the 2019 NCPA Annual Convention in San Diego.
Karla Palmer, JD: The big issue around CBD is the Farm Bill that passed December 20th of 2018, because with the passage of the Farm Bill, hemp-extracted CBD with a THC level of less than 0.3% was not considered to be within the federal definition of marijuana anymore. So, it was deregulated by the Congress and thus by DEA. So, if it’s a CBD product with less than 0.3% THC, it’s basically free reign for sale. And although that sounds like a good thing, about 5 days after its deregulation in the federal system, then-FDA Commissioner [Scott] Gottlieb released a statement to the press stating that notwithstanding Congress’s treatment of CBD, hemp-derived CBD pursuant to the passage of the Agricultural Improvement Acts, FDA would still regulate CBD’s use as a dietary supplement and as a drug product, and it would be vigorously enforcing the laws concerning its use in both of those forms.
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.